Adam J. Schoenfeld, MD, on Advanced Lung Cancer: Pumitamig Plus Elfetabart Drozuntecan
IASLC WCLC 2026
Adam J. Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from BNT324-01, an ongoing global phase Ib/II trial looking at pumitamig, an investigational PD-L1 × VEGF-A bispecific antibody, combined with elfetabart drozuntecan (BNT324/DB-1311), an investigational B7-H3–targeted antibody-drug conjugate, with a focus in small cell lung cancer (SCLC) (Abstract OA14.02).
Ricardo Sales dos Santos, MD, PhD, of the ProPulmão Institute, discusses data from the Third Brazilian Early Lung Cancer Trial (BRELT3). The study found low-dose computed tomography (CT) lung cancer screening using a mobile unit is feasible in socially vulnerable populations in resource-limited settings. Community-based recruitment, particularly through community health workers, improved the inclusion of high-risk and underserved groups, supporting the expansion of organized screening programs to promote equitable access and reduce lung cancer mortality (Abstract MO14.03).
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (Abstract PL03.03).
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor (TKI) therapy (Abstract PL03.06).
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, against pembrolizumab plus platinum chemotherapy in patients with advanced/metastatic HER2-mutant non–small cell lung cancer (NSCLC) (Abstract PL03.08).
Alberto A. Chiappori, MD, of Moffitt Cancer Center, discusses findings from a phase I trial looking at the safety and efficacy of LB2102, an autologous CAR-T cell therapy targeting DLL3 and armored with a dominant-negative TGF-beta receptor, in pretreated patients with small cell lung cancer (SCLC) (Abstract OA05.02).
